Two #Ebola therapeutics (REGN-EB3 & mAb114) show favorable results in clinical trial of investigational therapeutics in the DRC.

Tuesday, August 13, 2019 Two Ebola Therapeutics Show Favorable Results in Clinical Trial Preliminary results in a clinical trial of investigational Ebola therapeutics in the Democratic Republic of the Congo indicated that those individuals receiving the investigational treatments REGN-EB3 or mAb114 had a greater chance of survival compared to those participants in the other two treatment arms. The independent Data and Safety Monitoring Board (DSMB) recommended that the study be stopped and that all future patients be randomized to receive either REGN-EB3 or mAb114 in what is being considered an extension phase of the study. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID). This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107